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Neonatal abstinence syndrome (NAS) is a common compli-
cation of opioid dependency in pregnancy, particularlywhen
the latter is managed with maintenance methadone. The
likelihood of the infant developing NAS is greater for poly-
drug-misusing women and is reduced by breastfeeding.1,2
There is conﬂicting evidencewith regard towhether severity
of NAS is related to the maternal dose of methadone.2,3
Differences in pharmacokinetics and pharmacogenetics are
likely to inﬂuence the baby’s postnatal response to in utero
drug exposure.4
Variation in opioid metabolism is well recognized in
adults. The CYP2B6 gene encodes a cytochrome P450
mono-oxygenase enzyme involved in the metabolism of
methadone. Seventy-ﬁve percent of the Caucasian popula-
tion carries the homozygous, or wild-type, alleles at CYP2B6
516 G>T and 785 A>G, associated with normal enzyme
function.5 Single-nucleotide polymorphisms (SNPs) in
CYP2B6 are associatedwith variation inmethadone response
and carriers of the CYP2B66 genotype demonstrate slower
metabolism and higher trough plasma concentrations of
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Abstract Background Neonatal abstinence syndrome (NAS) in infants of methadone-main-
tained opioid-dependent (MMOD)mothers cannot be predicted in individual cases. We
investigated whether variation in infant genotype is associated with severity of NAS.
Methods This is a pilot observational cohort study of 21 MMOD mothers and their
newborns. Infant buccal swabs were obtained soon after delivery, together with a
maternal blood sample for the determination of maternal plasma methadone concen-
tration. Genomic variation in ﬁve opioid-related genes (ABCB1, COMT, CYP2B6, CYP2D6,
and OPRM1) was ascertained from infant buccal swabs and related to need for
pharmacological treatment of NAS.
Results Out of 21 infants, 11 (52%) required treatment for NAS. Mothers of treated
infants tended to have been prescribed higher doses of methadone, but plasma metha-
done concentrations did not differ between mothers of treated or untreated babies.
Treated and untreated babies did not differ in terms of method of feeding. Treated infants
weremore likely to carry the normal (homozygous) allele at 516 and 785 regions of CYP2B6
gene (p ¼ 0.015 and 0.023, respectively). There were no differences in any other genes
between infants who did or did not require treatment for NAS.
Conclusion Genomic variation in CYP2B6may explain, at least in part, severity of NAS.
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methadone compared with noncarriers.6–8 SNPs in OPRM1
and COMT opioid-related genes in the infant are associated
with NAS treatment and length of hospital stay,9 but to date
the association between SNPs in infant CYP2B6 and NAS has
not been reported.
Methods
All methadone-maintained opioid-dependent (MMOD)
mothers delivering after 36 weeks’ gestation in a single
maternity unit in Glasgow were eligible to participate in
this study if they were being accommodated with their baby
in the postnatal ward. Potential participants were identiﬁed
in the postnatal wards within 48 hours of delivery. Mothers
had been managed within a multidisciplinary service for
women with substance misuse problems; methadone main-
tenance was provided in collaboration with social work and
addiction services, tailored to symptoms. Sufﬁcient metha-
donewas prescribed to eliminate physical withdrawals, with
the aim of reducing to the lowest acceptable dose of metha-
done prior to delivery.
Following parental consent, a buccal swab (Catch-All;
Cambio Ltd., Cambridge) was obtained from the baby and a
venous blood sample obtained from the mother for estima-
tion of trough plasma methadone concentration.
Demographic data included maternal age and prescribed
dose ofmethadone at delivery, infant gestation, birthweight,
feeding method, and duration of hospital stay. Local policy
was to nurse all babies of MMOD mothers in the postnatal
ward with their mothers, regardless of the need for NAS
treatment unless the baby had another medical or social
indication for admission to the neonatal unit. NAS was
managed according to protocol using a local version of the
Lipsitz system for scoring.10 Infants who scored 5 or more on
two consecutive occasions and/or with poor feeding or
ongoing weight loss after 5 days were commenced on oral
morphine at 60 µg/kg six times daily. Dose was increased to
80 µg/kg per dose if the baby remained symptomatic;
otherwise morphine was weaned daily by 10 µg/kg/dose. If
NAS symptoms were not controlled by oral morphine, phe-
nobarbital was given in addition. Regardless of treatment, all
infants remained in the postnatal wardwith their mother for
a minimum of 5 days. Length of stay for treated babies was
determined by success of weaning of morphine; for treat-
ment periods longer than 10 to 12 days, the mother was
discharged from hospital and baby admitted to the neonatal
unit. Following weaning of oral morphine, phenobarbital
treatment could be continued as an outpatient. Breast-
feeding was encouraged for all babies. The research team
was not involved in any decision to treat an infant.
Buccal DNA was extracted from swabs by immersion in
QuickExtract DNA solution (Cambio Ltd., Cambridge).
Extracted DNA was analyzed for genomic variants in ﬁve
genes; ABCB1, COMT, CYP2B6, CYP2D6, and OPRM1 by LGC
Genomics using Kompetitive Allele Speciﬁc Polymerase chain
reaction (KASP). SNPs analyzed included ABCB1 1236 C>T,
2677G>T, and3435C>T; COMT98A>G, 186 C>T, 408 C>G,
and 472 A>G; CYP2B6 516 G>T and 785 A>G; CYP2D6 1707
T>delT; and OPRM1 118 A>G. The number of functioning
CYP2D6 alleles was ascertained using a Hy-Beacon assay (LGC
Genomics, Teddington). Maternal plasma samples were ana-
lyzed for methadone using liquid–liquid extraction and sub-
sequent gas chromatography mass spectrometry.
The inﬂuence of gestation, birth weight, methadone
dose, and plasma methadone concentration on NAS treat-
ment and length of hospital stay was determined using
independent sample t-tests (parametric) or Mann–Whitney
U-test (nonparametric data). Fisher’s exact test was used to
compare genotype distribution between infants who did
or did not require treatment for NAS. The study was
approved by West of Scotland Research Ethics Committee,
and written informed consent obtained from all participat-
ing mothers.
Results
Twenty-one of 22mothers approached agreed to participate;
samples were obtained from all 21 mother–infant pairs.
Gestation ranged from 36þ1 to 41þ0 (median 39þ0) weeks
and birth weight from 2,198 to 3,400 (median: 2,746) g.
Median maternal age at delivery was 32 (range: 25–42)
years. Median prescribed dose of methadone at delivery
was 55 (range: 2–100) mg; all mothers reported cigarette
smoking. Maternal plasmamethadone concentration ranged
from 20 to 720 (median: 200) ng/mL.
Eleven of 21 (52%) infants required treatment with oral
morphine,ﬁve of whomadditionally received phenobarbital.
Total duration of treatment varied from 8 to 134 (median:
44) days. There was no difference between babies who did or
did not receive treatment in terms of gestation, birth weight,
or method of feeding. Treated babies’ length of hospital stay
was longer (median: 20 [range: 10–42] vs. 7 [range: 5 – 11]
days; p < 0.005). Mothers of treated infants were older
(p ¼ 0.02) and tended to be prescribed higher doses of
methadone; plasma concentrations of methadone tended
to be higher for mothers of treated infants, but the difference
was not signiﬁcant (►Table 1). Allmothers and their partners
were of Caucasian origin.
Methadone-exposed infants who required treatment for
NAS were more likely to carry the normal (homozygous)
allele at 516 (n ¼ 8 [treated] vs. 1 [untreated]: p ¼ 0.015)
and 785 (n ¼ 7 [treated] vs. 2 [untreated]: p ¼ 0.023) regions
of the CYP2B6 gene (►Table 2). There were no differences
between treated and untreated babies in any other genes
studied.
Discussion
NAS is a common condition which accounts for a signiﬁcant
and increasing proportion of neonatal care worldwide.11
NAS is poorly predicted, resulting in many babies and their
mothers having a prolonged postnatal stay for observation of
developing NAS. Being able to predict NAS would reduce
unnecessary hospital stay and its associated costs, and also
afford an opportunity to investigate preemptive treatment
for babies likely to develop NAS.
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The CYP2B66 genotype is commonly reported in Cauca-
sian populations and is associatedwith slowermetabolismof
methadone.7 Within our infant population, the overall fre-
quency of the CYP2B66 genotype was 25%, consistent with
the general Caucasian population, but untreated infants
were much more likely to carry alleles associated with
decreased enzyme function at CYP2B6 516 G>T and 785
A>G. Doberczak et al12 reported more than 20 years ago that
severity of NAS was related to the rate of decline of the
infant’s plasma methadone concentration over the ﬁrst 4
days of life. Our ﬁndings are consistent with these ﬁndings,
with slower metabolism of methadone in the infant less
likely to result in abrupt withdrawal from transplacentally
acquired methadone and hence less severe NAS. Mothers of
treated babies tended to have been on higher doses of
methadone at delivery, but their plasma concentrations of
methadone were not signiﬁcantly higher, suggesting faster
maternal metabolism of methadone, consistent with their
infants. A genomic variant of CYP2B6 common tomother and
baby would explain both larger dosages of methadone
required by the mother to control cravings for opioid and
faster decline in neonatal plasma methadone concentration
reﬂected in more severe neonatal withdrawal. Genetic vari-
ation may also explain, at least in part, why there is differing
opinion as towhether maternal methadone dose is reﬂected
in the likelihood of the baby developing NAS.2,3
The weaknesses of this study are the small number of
patients, lack of toxicology to conﬁrm additional substance
misuse during pregnancy, and absence of maternal genetic
data. Mean plasma methadone concentration was almost
twice as high in mothers of treated babies, but the range of
values was very similar for both groups; small study num-
bers may have contributed to a type II error. Additional
substance misuse is notoriously difﬁcult to ascertain from
maternal history, but within the population attending our
service polydrug use is common and positively correlated
with the prescribed dose of methadone.2 A previous study
demonstrated ongoing illicit drug use in 90% of our MMOD
mothers, predominantly benzodiazepines and heroin,13 and
all of the mothers included in this study reported cigarette
smoking. It is possible that both nicotine and additional
substances of abuse contributed to the development of NAS.
ABCB1 affects drug deposition rather than metabolism
and SNPs in this gene are unrelated to opioid addiction in
adults.7 Consistent with published literature, we did not see
differences in ABCB1 associated with the likelihood of the
baby requiring treatment for NAS.9 Maternal CYP2D6 geno-
type has been associated with higher than predicted conver-
sion of codeine to morphine and fatal respiratory depression
in a breast-fed baby, but the latter genotype is uncommon in
the Caucasian population.14 We did not see any association
between NAS and either of the two CYP2D6 genotypes tested
Table 1 Demographic and genomic data for methadone-exposed babies according to treatment of neonatal abstinence
syndrome (NAS)
Variables Infants requiring NAS
treatment (n ¼ 11)
Infants not requiring NAS
treatment (n ¼ 10)
p-Value
Gestation (wk) (median [range]) 39þ1 (36þ5–41þ0) 38þ4 (36þ1–40þ4) 0.408
Birth weight (g) (median [range]) 2,731 (2,300–3,240) 2,876 (2,198–3,400) 0.378
Length of hospital stay (d) (median [range]) 19 (10–42) 7 (5–11) 0.004
Maternal age (y) (median [range]) 34 (28–42) 30 (25–37) 0.021
Maternal methadone dose (mg) (median [range]) 65 (30–100) 54 (2–100) 0.391
Maternal plasma methadone concentration (µg/L)
(median [range])
320 (80–660) 165 (20–720) 0.315
Table 2 Relative frequency of different genotypes for treated
(n ¼ 11) and untreated (n ¼ 10) infants
Gene Treated
(n)
Untreated
(n)
p-Value
ABCB1 1236 CC/CT 7 7 1.0
TT 2 3
2677 GG/GT 8 7 1.0
TT 2 3
3435 CC/CT 5 7 0.65
TT 4 3
COMT 186 CC/CT 6 6 0.638
TT 4 2
472 AA 4 6 0.303
GG/GA 1 9
408 CG/GG 4 7 0.63
CC 4 3
98 AA 4 4 1.0
GG/GA 6 6
CYP2D6 1707 TT 9 10 1.0
deIT 1 0
Number of
functioning
alleles
1 0 2 0.474
2 10 8
OPRM1 118 AA 8 9 1.0
GG/GA 1 1
CYP2B6 516 GG 8 1 0.015
GT 2 7
785 AA 7 2 0.023
AG 2 8
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in this study. Small study numbers may explain our failure to
replicate the ﬁndings ofWachman et al, inwhose study SNPs
in both OPRM1 and COMT predicted NAS.9
The strengths of this small pilot study are that mothers and
babies were cared for in one facility, with a practiced and
consistent approach tomanagementofNAS. Persons caring for
the babies were unaware of the infant’s genotype. Evenwithin
a small number of patients, genomic variation in CYP2B6
between treated and untreated babies was signiﬁcant.
Future studies should consider maternal genotype and its
relationship to infant genotype and/or the prediction of NAS
as well as associated maternal polydrug use.
Conclusion
Genomic variation in CYP2B6 in the newborn is associated
with severity of NAS; this has not previously been reported.
Better understanding of the role of pharmacogenetics in
the etiology of NAS may result in improved care for mother
and baby.
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